<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15528">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02904733</url>
  </required_header>
  <id_info>
    <org_study_id>EMERGE</org_study_id>
    <nct_id>NCT02904733</nct_id>
  </id_info>
  <brief_title>Validation Study of mHealth Technology in HIV to Improve Empowerment and Healthcare Utilisation: Research and Innovation to Generate Evidence for Personalised Care (EmERGE)</brief_title>
  <acronym>EMERGE</acronym>
  <official_title>Validation Study of mHealth Technology in HIV to Improve Empowerment and Healthcare Utilisation: Research and Innovation to Generate Evidence for Personalised Care (EmERGE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brighton and Sussex University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituut Voor Tropische Geneeskunde (ITM), Antwerp, Belgium.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinika za infektivne bolesti (KIB), Zagreb, Croatia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar de Lisboa Central</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Brighton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Podmedics, ( POD), Northwood, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Politecnica de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Prospective Monitoring System HIV Health-economics Collaboration, (NPMS), Richmond, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Aids Treatment Group (EATG), Brussels, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>mHealth Futures LTD, Brighton, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A large (3900 patients) cohort study, undertaken in five European sites to validate in a
      mHealth platform to enable self-management of HIV in patients with stable disease using a
      tailored HTA process, Model for Assessment of Telemedicine Applications (MAST), specifically
      developed for the assessment of mHealth solutions.

      As site recruitment will be sequential and the recruitment period will last 18 months, a
      maximum follow-up of 35 Months will be undertaken. Study visits will take place at baseline
      defined as the time of mHealth introduction, months 6, 12, 18, 24 and 30.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Number of Study Centres: 5 Duration of Study: 35 Months Criteria for Evaluation: Usability
      of the mHealth platform, patient self-management and empowerment, clinical safety
      (virological suppression maintenance, CD4 count, laboratory parameters, adverse events and
      adherence), quality of life and self-economy will be assessed by questionnaires and
      laboratory parameters.

      Routine data on patient demographics, treatment and investigations which will include viral
      load, CD4, haematology, biochemistry and urine sample. Patient Activation Measure, Quality
      of life, adherence questionnaire and economic questionnaires will be performed at baseline
      and at months 12 and 24. Satisfaction System Usability Scale will be evaluated at month 12
      and 24.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Patient Activation Measure (PAM-13) questionnaire from baseline</measure>
    <time_frame>months 12 and 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Satisfaction System Usability Scale (SUS)</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of virological suppression (HIV-1 RNA &lt;50 c/ml)</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 count</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood lipid profile</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of life (EQ-5D-5L questionnaire) from baseline</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of life (PROQOL-HIV questionnaire) from baseline</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in adherence quantified by Morisky-Green questionnaire</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with changes in ART from baseline</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on self-reported economic questionnaire aspects from baseline</measure>
    <time_frame>months 12 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3900</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>mHealth platform</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stable HIV-1 infected subjects will be followed-up using an mHealth platform. The platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to healthcare providers. The minimum length of follow-up will be 12 months and the maximum 35 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mHealth platform</intervention_name>
    <arm_group_label>mHealth platform</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented HIV-1 infection

          2. Aged at least 18 years old

          3. Able to give informed consent

          4. In possession of a smartphone, tablet, or similar technology supporting the mHealth
             platform

          5. Stable on ART: Defined as ART should be unchanged for at least 3 months and viral
             load undetectable (&lt;50 copies/ml) for at least 6 months.

          6. Clinically stable from an HIV perspective: Defined as without opportunistic infection
             or AIDS related cancers within the previous 12 months

        Exclusion Criteria:

          1. Aged less than 18 years

          2. Pregnant

          3. Participating in a clinical trial or receiving an investigational medication

          4. Unable to comprehend the patient information sheet

          5. Unable to comprehend the instructions for using the mHealth platform

          6. Considered for any other reason by their regular physician to be unsuitable for study
             participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Whetham, MD</last_name>
    <phone>+44 1273 523081</phone>
    <email>Jennifer.Whetham@bsuh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agathe León, MD</last_name>
    <phone>+34932275400</phone>
    <phone_ext>2447</phone_ext>
    <email>aleon@clinic.ub.es</email>
  </overall_contact_backup>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 13, 2016</lastchanged_date>
  <firstreceived_date>July 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Agathe LEON</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
